Leading Brazilian Information Security Specialist Kryptus Expands Its Activities in the EMEA Region
12.5.2020 17:55:00 EEST | Business Wire | Press release
Seeking to consolidate its presence and develop new businesses in Europe, Middle East and Africa (EMEA), Brazilian Kryptus, specialized in cryptography and information security, announces the expansion of its international activities with the opening of a new unit of the company in Switzerland. The initiative is focused on offering technical support in the region, as well as develop the market, regional channel partners, and respond to local requirements. The move includes the announcement of Thierry Martin as the new director for EMEA and the head of the Swiss branch.
With a strong cybersecurity background, Martin is an engineer who has led several different technology companies in Europe and Brazil. The executive has also been a member of the Kryptus board in 2016 and 2017.
Currently providing solutions to financial institutions, private companies, and governments around the globe, Kryptus aims through this expansion to reach more customers with its competitive and unique product portfolio. The offerings include kNET, its high-performance HSM with unbreakable encryption, and Commguard, its flexible line of link encryptors.
"Kryptus can deliver world-class, trustworthy, and secure cryptography solutions for critical applications. Our presence in the region allows the optimization of services for customized or custom-developed products, providing a strong value proposition in the EMEA region," says Thierry Martin.
According to Roberto Gallo, founder & CEO of Kryptus, expanding to the EMEA region strengthens the company's position as a strategic provider of cyberdefense for governments and enterprises. "Kryptus can now extend its technology offering to Europe, Middle East, and Africa, based on relevant certifications and high performance," he points out.
With its Headquarter in Campinas, Kryptus was founded in 2003 and counts among its customers companies like BSH (a BOSCH Gmbh subsidiary), Claro Brasil (America Móvil Group), Certisign (exclusive Verisign partner in Brazil), Iron Mountain, iFood and Embraer. Granted the status of Strategic Defense Company (EED) by the Brazilian Defense Council, Kryptus has gained the trust - as a supplier from a neutral country - of several government agencies to protect their sovereignty. Among such customers with the highest security requirements, Kryptus delivered government-grade solutions to the Peruvian Navy, the Colombian Army and the Brazilian Army, Air Force, Navy, Intelligence Agency, Ministry of Foreign Affairs, and Superior Electoral Court, as well as to several other governments.
About Thierry Martin
Thierry Martin was born in Switzerland where he studied Electronics and Computer Science. He has professional experience in various areas of technology, among them Digital TV, Cyber Security, Electronics, and Telecommunications. Along his career he has lived and worked in Switzerland, Spain, the United Kingdom, and Brazil, as well as worked extensively with the United States and Asia. He has held executive positions in companies like Nagra, Kudelski Security, Selectron Systems AG, and Mouvent AG.
About Kryptus
Kryptus is a provider of solutions in Information Security. With 17 years of history and HQ in Campinas (SP), Kryptus SA is an independent Brazilian company that has been growing consistently for the past 10 years, focusing on long term actions, scientific and technological plans, and understanding the mission of its clients in the business lines it develops. Kryptus is a partner of the Kudelski Group. Kryptus is a Brazilian Strategic Defense Company (EED), a status granted by the Brazilian Defense Council.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005624/en/
Contact information
Thierry Martin
+41 79 932 19 23
thierry.martin@kryptus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom